Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Sep;121(3):539-43.
doi: 10.1046/j.1365-2249.2000.01320.x.

Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35

B Grigolo  1 , I Mazzetti, R Meliconi, S Bazzi, R Scorza, M Candela, A Gabrielli, A Facchini
Affiliations

Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35

B Grigolo et al. Clin Exp Immunol. 2000 Sep.

Abstract

We have previously detected autoantibodies against topoisomerase II alpha (anti-topo II alpha) in sera from patients with idiopathic pulmonary fibrosis. To determine whether anti-topo II alpha is also present in systemic sclerosis (SSc) patients with pulmonary involvement, we screened sera from 92 patients and 34 healthy controls. Presence of anti-topo II alpha was investigated with respect to clinical and serological features, including the frequencies of HLA class I and II alleles. Anti-topo II alpha was detected in 20/92 (21.7%) patients. No association was found with either anti-topoisomerase I (Scl-70 or anti-topo I) or anti-centromere antibodies. However, anti-topo II alpha was associated with the presence of pulmonary hypertension (PHT) (as opposed to pulmonary fibrosis), and with a decrease of carbon monoxide diffusing capacity. Anti-topo II alpha was strongly associated with the presence of the class I antigen HLA-B35. No significant association was found with HLA class II antigens. HLA-B35 also turned out to be associated with the presence of PHT. These results indicate that in SSc patients, the presence of anti-topo II alpha is associated with PHT, and that the simultaneous presence of HLA-B35 seems to add to the risk of developing PHT.

PubMed Disclaimer

References

    1. Medsger Ta., Jr . Systemic sclerosis (scleroderma): clinical aspects. In: Koopman WJ, editor. Arthritis and allied conditions. 13. Philadelphia: Williams & Wilkins; 1997. pp. 1433–64.
    1. Douvas AS, Achten M, Tan EM. Identification of a nuclear protein (Scl-70) as a major target of human antinuclear antibodies in Scleroderma. J Biol Chem. 1979;254:10514–22. - PubMed
    1. Shero JH, Borwell B, Rothfield NF, Earnshaw WC. High titer of autoantibodies to Topoisomerase I (Scl-70) in sera from scleroderma patients. Science. 1986;231:737–40. - PubMed
    1. Martin L, Pauls JD, Ryan JP, Fritzler MJ. Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and hystone. Ann Rheum Dis. 1993;52:780–4. - PMC - PubMed
    1. Okano Y, Steen VD, Medsger Ta., Jr Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med. 1993;119:1005–13. - PubMed

Publication types